Biothera Pharmaceuticals to Participate in Webinar on Utilizing Innate Immune Mechanisms to Trigger Anti-Cancer Responses
EAGAN, MN — March 25, 2019 — Biothera Pharmaceuticals, Inc. President and Chief Scientific Officer Jeremy Graff, Ph.D., will participate in a webinar tomorrow on the development of therapies targeting innate immune mechanisms to overcome cancer defenses and initiate anti-tumor responses. The Scientist magazine will host the webinar, “Keeping Cancer in Check: Innate Immunity and Checkpoint Inhibitors,” from 2:30-4:00pm Eastern Time. Registration is free.
In addition to Dr. Graff, speakers include Andrea van Elsas, Ph.D., Chief Scientific Officer of Aduro Biotech, Inc., and Timo van den Berg, Ph.D., Professor of Immunotherapy, Departments of Molecular Cell Biology and Immunology, VU Medical Center, Amsterdam.
About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held clinical stage immuno-oncology company developing Imprime PGG, a Phase 2 cancer immunotherapy that has been shown in preclinical studies to enhance the efficacy of anti-cancer immune responses in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenic antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in Phase 2 studies in metastatic triple negative breast cancer and advanced melanoma. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. In addition, Biothera Pharmaceuticals has a clinical collaboration agreement with Genentech to study Imprime PGG in combination with TECENTRIQ® (atezolizumab) and AVASTIN® (bevacizumab) in metastatic colorectal cancer.
Biothera Pharmaceuticals, Inc.